The George Washington University is one of four US sites conducting a Phase I clinical trial to test the safety and immune responses of two mRNA vaccine antigens for HIV on 56 healthy adults. The GW Vaccine Research Unit is running one of the study sites and acting as the processing lab and biorepository. The unit has partnered with study sponsor IAVI on two other HIV vaccine-related Phase I clinical trials and conducted several other clinical vaccine trials, including one for the FDA-authorized COVID-19 vaccine. Continue reading to see more about what GW is doing for the First Human Trial of mRNA-based HIV Vaccine.
GW Participating in the First Human Trial of mRNA-based HIV Vaccine
Latest News
Dr. David Diemert, the director of the George Washington University Vaccine Research Unit, weighs in on President Donald Trump's executive order pushing for revisions to how children in the US are vaccinated and what that means for the future.
The GW VRU is a site for a clinical trial to examine Pfizer's new C. diff vaccine.
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
